Kaival Brands Innovations Group Inc
kaivalbrands.comKaival Brands Innovations Group Inc (NASDAQ: KAVL) is a consumer products distribution company that held an exclusive distribution agreement with Bidi Vapor LLC for electronic nicotine delivery system (ENDS) products, primarily disposable vaporizer devices. Revenue was generated through product sales under that exclusive distribution arrangement. As of the 10-K filed January 29, 2026, covering fiscal year ended October 31, 2025, the company reported going concern doubt, working capital of approximately $100 thousand, and total cash of approximately $0.5 million. Total operating expenses were approximately $17.1 million for FY2025, including a $9.9 million impairment of intangible assets and $4.6 million in professional fees, against $8.3 million in FY2024. The company carried federal net operating loss carryforwards of approximately $34.2 million as of FY2025. QuikTrip Corporation accounted for 100% of accounts receivable from customers as of October 31, 2024, indicating extreme customer concentration. The company has disclosed it does not expect to generate sufficient revenue to support operations for at least twelve months from the filing date.
Products & Services
Exclusive distribution of disposable vaporizer devices manufactured by Bidi Vapor LLC under an amended and restated distribution agreement. The agreement covered current products and granted rights of first refusal on future products from Bidi Vapor.
Revenue Model
Product sales of ENDS devices distributed exclusively under an agreement with Bidi Vapor LLC. QuikfillRx (operating as Kaival Marketing Services) provided sales management, marketing, and analytics support under a services agreement.
Customers & Markets
Convenience store and fuel retail channels. QuikTrip Corporation represented 100% of accounts receivable from customers as of October 31, 2024, indicating single-customer concentration. End market is adult consumers of electronic nicotine delivery system products.
Geographic Exposure
United States, based on references to FDA and U.S. regulatory proceedings including an International Trade Commission matter (Inv. No. 337-TA-1410) involving Bidi Vapor.
Financial Snapshot
Loading...
